Symbols / ABT $102.30 -0.55% Abbott Laboratories
ABT Chart
About
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. The company also provides cancer screening and diagnostic test products. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 177.76B |
| Enterprise Value | 184.59B | Income | 6.50B | Sales | 44.33B |
| Book/sh | 30.02 | Cash/sh | 5.14 | Dividend Yield | 245.00% |
| Payout | 63.44% | Employees | 115000 | IPO | — |
| P/E | 27.50 | Forward P/E | 16.76 | PEG | — |
| P/S | 4.01 | P/B | 3.41 | P/C | — |
| EV/EBITDA | 15.34 | EV/Sales | 4.16 | Quick Ratio | 1.02 |
| Current Ratio | 1.58 | Debt/Eq | 26.79 | LT Debt/Eq | — |
| EPS (ttm) | 3.72 | EPS next Y | 6.10 | EPS Growth | -80.90% |
| Revenue Growth | 4.40% | Earnings | 2026-04-16 | ROA | 6.63% |
| ROE | 12.96% | ROIC | — | Gross Margin | 56.66% |
| Oper. Margin | 21.62% | Profit Margin | 14.72% | Shs Outstand | 1.74B |
| Shs Float | 1.73B | Short Float | 1.28% | Short Ratio | 2.35 |
| Short Interest | — | 52W High | 139.06 | 52W Low | 100.88 |
| Beta | 0.78 | Avg Volume | 11.52M | Volume | 7.13M |
| Target Price | $132.28 | Recom | Buy | Prev Close | $102.87 |
| Price | $102.30 | Change | -0.55% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-06 | main | Evercore ISI Group | Outperform → Outperform | $134 |
| 2026-03-31 | main | BTIG | Buy → Buy | $131 |
| 2026-03-11 | main | Citigroup | Buy → Buy | $136 |
| 2026-02-02 | main | Barclays | Overweight → Overweight | $142 |
| 2026-01-29 | up | Freedom Broker | Hold → Buy | $120 |
| 2026-01-23 | main | Citigroup | Buy → Buy | $140 |
| 2026-01-23 | main | Bernstein | Outperform → Outperform | $125 |
| 2026-01-23 | main | RBC Capital | Outperform → Outperform | $135 |
| 2026-01-23 | main | Oppenheimer | Outperform → Outperform | $132 |
| 2026-01-23 | main | Evercore ISI Group | Outperform → Outperform | $138 |
| 2026-01-23 | main | Piper Sandler | Overweight → Overweight | $135 |
| 2026-01-23 | main | BTIG | Buy → Buy | $140 |
| 2026-01-09 | main | Bernstein | Outperform → Outperform | $154 |
| 2026-01-05 | main | Barclays | Overweight → Overweight | $169 |
| 2025-11-20 | reit | BTIG | Buy → Buy | $145 |
| 2025-10-17 | main | Barclays | Overweight → Overweight | $162 |
| 2025-10-16 | main | Raymond James | Outperform → Outperform | $146 |
| 2025-10-16 | main | Evercore ISI Group | Outperform → Outperform | $142 |
| 2025-10-16 | reit | RBC Capital | Outperform → Outperform | $147 |
| 2025-10-16 | main | Wells Fargo | Overweight → Overweight | $146 |
News
RSS: Latest ABT news- Abbott Laboratories (ABT) stock price, news, quote and history - Yahoo Finance UK Sat, 04 Apr 2026 23
- Evercore ISI Lowers Price Target for Abbott Laboratories (ABT) t - GuruFocus Mon, 06 Apr 2026 16
- Abbott Laboratories $ABT Shares Acquired by BXM Wealth LLC - MarketBeat Mon, 06 Apr 2026 08
- Abbott Laboratories (ABT) likely to benefit from nutrition segment recovery - MSN Mon, 06 Apr 2026 04
- Abbott Stock Sits 26% Off Its Peak While Analysts Back a $132 Mean Price Target - TIKR.com Fri, 03 Apr 2026 14
- Abbott Laboratories (ABT) director receives 382 stock equivalent units as fees - Stock Titan hu, 02 Apr 2026 21
- GEHC or ABT: Which Is the Better Value Stock Right Now? - qz.com hu, 02 Apr 2026 00
- Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade) (NYSE:ABT) - Seeking Alpha Wed, 01 Apr 2026 17
- ABT Price History for Abbott Laboratories Stock - Barchart hu, 02 Apr 2026 07
- Rathbones Group PLC Increases Position in Abbott Laboratories $ABT - MarketBeat Mon, 06 Apr 2026 11
- Abbott (ABT) Stock Sinks As Market Gains: Here's Why - finance.yahoo.com Mon, 02 Mar 2026 08
- Abbott (ABT) director Robert Alpern awarded 76 stock equivalent units as fees - Stock Titan hu, 02 Apr 2026 21
- GEHC vs. ABT: Which Stock Is the Better Value Option? - finance.yahoo.com Mon, 16 Mar 2026 07
- Abbott (ABT) director Gonzalez receives 321 stock equivalent units as fees - Stock Titan hu, 02 Apr 2026 21
- Is Trending Stock Abbott Laboratories (ABT) a Buy Now? - finance.yahoo.com Wed, 18 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
44,328.00
+5.67%
|
41,950.00
+4.59%
|
40,109.00
-8.12%
|
43,653.00
|
| Operating Revenue |
|
44,328.00
+5.67%
|
41,950.00
+4.59%
|
40,109.00
-8.12%
|
43,653.00
|
| Cost Of Revenue |
|
19,319.00
+3.28%
|
18,706.00
+4.07%
|
17,975.00
-6.10%
|
19,142.00
|
| Reconciled Cost Of Revenue |
|
17,885.00
+2.99%
|
17,366.00
+4.00%
|
16,698.00
-6.65%
|
17,888.00
|
| Gross Profit |
|
25,009.00
+7.59%
|
23,244.00
+5.01%
|
22,134.00
-9.70%
|
24,511.00
|
| Operating Expense |
|
16,956.00
+3.27%
|
16,419.00
+4.87%
|
15,656.00
-3.05%
|
16,149.00
|
| Research And Development |
|
2,942.00
+3.45%
|
2,844.00
+3.76%
|
2,741.00
-5.09%
|
2,888.00
|
| Selling General And Administration |
|
12,332.00
+5.43%
|
11,697.00
+6.83%
|
10,949.00
-2.66%
|
11,248.00
|
| Total Expenses |
|
36,275.00
+3.27%
|
35,125.00
+4.44%
|
33,631.00
-4.70%
|
35,291.00
|
| Operating Income |
|
8,053.00
+17.99%
|
6,825.00
+5.36%
|
6,478.00
-22.53%
|
8,362.00
|
| Total Operating Income As Reported |
|
8,053.00
+17.99%
|
6,825.00
+5.36%
|
6,478.00
-22.53%
|
8,362.00
|
| EBITDA |
|
12,075.00
+11.91%
|
10,790.00
+2.33%
|
10,544.00
-13.08%
|
12,131.00
|
| Normalized EBITDA |
|
12,025.00
+11.73%
|
10,763.00
+1.68%
|
10,585.00
-12.76%
|
12,133.00
|
| Reconciled Depreciation |
|
3,116.00
-3.17%
|
3,218.00
-0.77%
|
3,243.00
-0.73%
|
3,267.00
|
| EBIT |
|
8,959.00
+18.32%
|
7,572.00
+3.71%
|
7,301.00
-17.63%
|
8,864.00
|
| Total Unusual Items |
|
50.00
+85.19%
|
27.00
+165.85%
|
-41.00
-1950.00%
|
-2.00
|
| Total Unusual Items Excluding Goodwill |
|
50.00
+85.19%
|
27.00
+165.85%
|
-41.00
-1950.00%
|
-2.00
|
| Special Income Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
6,524.00
-51.32%
|
13,402.00
+134.18%
|
5,723.00
-17.45%
|
6,933.00
|
| Pretax Income |
|
8,466.00
+20.72%
|
7,013.00
+5.24%
|
6,664.00
-19.77%
|
8,306.00
|
| Net Non Operating Interest Income Expense |
|
-185.00
+13.95%
|
-215.00
+14.68%
|
-252.00
+32.80%
|
-375.00
|
| Interest Expense Non Operating |
|
493.00
-11.81%
|
559.00
-12.24%
|
637.00
+14.16%
|
558.00
|
| Net Interest Income |
|
-185.00
+13.95%
|
-215.00
+14.68%
|
-252.00
+32.80%
|
-375.00
|
| Interest Expense |
|
493.00
-11.81%
|
559.00
-12.24%
|
637.00
+14.16%
|
558.00
|
| Interest Income Non Operating |
|
308.00
-10.47%
|
344.00
-10.65%
|
385.00
+110.38%
|
183.00
|
| Interest Income |
|
308.00
-10.47%
|
344.00
-10.65%
|
385.00
+110.38%
|
183.00
|
| Other Income Expense |
|
598.00
+48.39%
|
403.00
-7.99%
|
438.00
+37.30%
|
319.00
|
| Other Non Operating Income Expenses |
|
548.00
+45.74%
|
376.00
-21.50%
|
479.00
+49.22%
|
321.00
|
| Gain On Sale Of Security |
|
50.00
+85.19%
|
27.00
+165.85%
|
-41.00
-1950.00%
|
-2.00
|
| Tax Provision |
|
1,942.00
+130.40%
|
-6,389.00
-778.96%
|
941.00
-31.46%
|
1,373.00
|
| Tax Rate For Calcs |
|
0.00
+9.05%
|
0.00
+48.94%
|
0.00
-14.70%
|
0.00
|
| Tax Effect Of Unusual Items |
|
11.45
+101.94%
|
5.67
+198.08%
|
-5.78
-1648.62%
|
-0.33
|
| Net Income Including Noncontrolling Interests |
|
6,524.00
-51.32%
|
13,402.00
+134.18%
|
5,723.00
-17.45%
|
6,933.00
|
| Net Income From Continuing Operation Net Minority Interest |
|
6,524.00
-51.32%
|
13,402.00
+134.18%
|
5,723.00
-17.45%
|
6,933.00
|
| Net Income From Continuing And Discontinued Operation |
|
6,524.00
-51.32%
|
13,402.00
+134.18%
|
5,723.00
-17.45%
|
6,933.00
|
| Net Income Continuous Operations |
|
6,524.00
-51.32%
|
13,402.00
+134.18%
|
5,723.00
-17.45%
|
6,933.00
|
| Net Income Discontinuous Operations |
|
—
|
—
|
—
|
0.00
|
| Normalized Income |
|
6,485.45
-51.53%
|
13,380.67
+132.38%
|
5,758.22
-16.96%
|
6,934.67
|
| Net Income Common Stockholders |
|
6,524.00
-51.32%
|
13,402.00
+134.18%
|
5,723.00
-17.45%
|
6,933.00
|
| Diluted EPS |
|
3.72
-51.31%
|
7.64
+134.36%
|
3.26
-16.62%
|
3.91
|
| Basic EPS |
|
3.76
-51.46%
|
7.74
+134.50%
|
3.30
-17.28%
|
3.99
|
| Basic Average Shares |
|
1,736.60
+0.28%
|
1,731.70
-0.14%
|
1,734.08
-0.21%
|
1,737.80
|
| Diluted Average Shares |
|
1,749.00
+0.06%
|
1,748.00
-0.06%
|
1,749.00
-0.85%
|
1,764.00
|
| Diluted NI Availto Com Stockholders |
|
6,524.00
-51.32%
|
13,402.00
+134.18%
|
5,723.00
-17.45%
|
6,933.00
|
| Amortization |
|
1,682.00
-10.44%
|
1,878.00
-4.48%
|
1,966.00
-2.33%
|
2,013.00
|
| Amortization Of Intangibles Income Statement |
|
1,682.00
-10.44%
|
1,878.00
-4.48%
|
1,966.00
-2.33%
|
2,013.00
|
| Depreciation Amortization Depletion Income Statement |
|
1,682.00
-10.44%
|
1,878.00
-4.48%
|
1,966.00
-2.33%
|
2,013.00
|
| Depreciation And Amortization In Income Statement |
|
1,682.00
-10.44%
|
1,878.00
-4.48%
|
1,966.00
-2.33%
|
2,013.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
86,713.00
+6.51%
|
81,414.00
+11.20%
|
73,214.00
-1.64%
|
74,438.00
|
| Current Assets |
|
25,996.00
+9.89%
|
23,656.00
+4.35%
|
22,670.00
-10.13%
|
25,224.00
|
| Cash Cash Equivalents And Short Term Investments |
|
8,939.00
+12.20%
|
7,967.00
+9.45%
|
7,279.00
-28.43%
|
10,170.00
|
| Cash And Cash Equivalents |
|
8,522.00
+11.90%
|
7,616.00
+10.44%
|
6,896.00
-30.22%
|
9,882.00
|
| Other Short Term Investments |
|
417.00
+18.80%
|
351.00
-8.36%
|
383.00
+32.99%
|
288.00
|
| Receivables |
|
10,569.00
+11.31%
|
9,495.00
+7.64%
|
8,821.00
-0.68%
|
8,881.00
|
| Accounts Receivable |
|
7,929.00
+14.50%
|
6,925.00
+5.48%
|
6,565.00
+5.58%
|
6,218.00
|
| Gross Accounts Receivable |
|
8,419.00
+14.33%
|
7,364.00
+5.06%
|
7,009.00
+4.33%
|
6,718.00
|
| Allowance For Doubtful Accounts Receivable |
|
-490.00
-11.62%
|
-439.00
+1.13%
|
-444.00
+11.20%
|
-500.00
|
| Other Receivables |
|
2,640.00
+2.72%
|
2,570.00
+13.92%
|
2,256.00
-15.28%
|
2,663.00
|
| Inventory |
|
6,488.00
+4.75%
|
6,194.00
-5.72%
|
6,570.00
+6.43%
|
6,173.00
|
| Raw Materials |
|
1,608.00
-2.78%
|
1,654.00
-8.97%
|
1,817.00
+7.64%
|
1,688.00
|
| Work In Process |
|
904.00
+7.62%
|
840.00
+4.09%
|
807.00
+18.68%
|
680.00
|
| Finished Goods |
|
3,976.00
+7.46%
|
3,700.00
-6.23%
|
3,946.00
+3.71%
|
3,805.00
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Total Non Current Assets |
|
60,717.00
+5.12%
|
57,758.00
+14.27%
|
50,544.00
+2.70%
|
49,214.00
|
| Net PPE |
|
11,816.00
+10.87%
|
10,658.00
+4.96%
|
10,154.00
+10.83%
|
9,162.00
|
| Gross PPE |
|
25,222.00
+10.91%
|
22,740.00
+3.68%
|
21,933.00
+8.51%
|
20,212.00
|
| Accumulated Depreciation |
|
-13,406.00
-10.96%
|
-12,082.00
-2.57%
|
-11,779.00
-6.60%
|
-11,050.00
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
541.00
+2.46%
|
528.00
-0.19%
|
529.00
+3.52%
|
511.00
|
| Buildings And Improvements |
|
4,543.00
+7.99%
|
4,207.00
+1.11%
|
4,161.00
+2.66%
|
4,053.00
|
| Machinery Furniture Equipment |
|
—
|
—
|
—
|
—
|
| Construction In Progress |
|
2,567.00
+3.18%
|
2,488.00
+20.54%
|
2,064.00
+39.08%
|
1,484.00
|
| Other Properties |
|
17,571.00
+13.24%
|
15,517.00
+2.23%
|
15,179.00
+7.17%
|
14,164.00
|
| Goodwill And Other Intangible Assets |
|
29,561.00
-0.65%
|
29,755.00
-8.43%
|
32,494.00
-2.28%
|
33,253.00
|
| Goodwill |
|
24,035.00
+4.01%
|
23,108.00
-2.41%
|
23,679.00
+3.86%
|
22,799.00
|
| Other Intangible Assets |
|
5,526.00
-16.86%
|
6,647.00
-24.59%
|
8,815.00
-15.68%
|
10,454.00
|
| Investments And Advances |
|
918.00
+3.61%
|
886.00
+10.89%
|
799.00
+4.31%
|
766.00
|
| Other Investments |
|
321.00
-3.60%
|
333.00
+36.48%
|
244.00
+17.31%
|
208.00
|
| Non Current Deferred Assets |
|
—
|
—
|
—
|
6,033.00
|
| Non Current Deferred Taxes Assets |
|
—
|
—
|
—
|
6,033.00
|
| Other Non Current Assets |
|
18,422.00
+11.93%
|
16,459.00
+131.91%
|
7,097.00
+17.64%
|
6,033.00
|
| Total Liabilities Net Minority Interest |
|
33,942.00
+1.28%
|
33,513.00
-2.54%
|
34,387.00
-8.38%
|
37,533.00
|
| Current Liabilities |
|
16,496.00
+16.52%
|
14,157.00
+2.28%
|
13,841.00
-10.64%
|
15,489.00
|
| Payables And Accrued Expenses |
|
13,463.00
+6.37%
|
12,657.00
-0.81%
|
12,761.00
-3.60%
|
13,238.00
|
| Payables |
|
6,588.00
+2.39%
|
6,434.00
+0.66%
|
6,392.00
-1.28%
|
6,475.00
|
| Accounts Payable |
|
4,240.00
+1.07%
|
4,195.00
-2.33%
|
4,295.00
-6.77%
|
4,607.00
|
| Other Payable |
|
682.00
+9.82%
|
621.00
-4.46%
|
650.00
+1.88%
|
638.00
|
| Dividends Payable |
|
1,097.00
+7.13%
|
1,024.00
+7.23%
|
955.00
+7.67%
|
887.00
|
| Current Accrued Expenses |
|
6,875.00
+10.48%
|
6,223.00
-2.29%
|
6,369.00
-5.83%
|
6,763.00
|
| Employee Benefits |
|
2,125.00
+13.03%
|
1,880.00
-4.28%
|
1,964.00
+10.09%
|
1,784.00
|
| Total Tax Payable |
|
569.00
-4.21%
|
594.00
+20.73%
|
492.00
+43.44%
|
343.00
|
| Income Tax Payable |
|
569.00
-4.21%
|
594.00
+20.73%
|
492.00
+43.44%
|
343.00
|
| Current Debt And Capital Lease Obligation |
|
3,033.00
+102.20%
|
1,500.00
+38.89%
|
1,080.00
-52.02%
|
2,251.00
|
| Current Debt |
|
3,033.00
+102.20%
|
1,500.00
+38.89%
|
1,080.00
-52.02%
|
2,251.00
|
| Total Non Current Liabilities Net Minority Interest |
|
17,446.00
-9.87%
|
19,356.00
-5.79%
|
20,546.00
-6.80%
|
22,044.00
|
| Long Term Debt And Capital Lease Obligation |
|
10,827.00
-19.92%
|
13,521.00
-7.06%
|
14,548.00
-5.93%
|
15,465.00
|
| Long Term Debt |
|
9,896.00
-21.62%
|
12,625.00
-7.16%
|
13,599.00
-6.36%
|
14,522.00
|
| Long Term Capital Lease Obligation |
|
931.00
+3.91%
|
896.00
-5.58%
|
949.00
+0.64%
|
943.00
|
| Non Current Pension And Other Postretirement Benefit Plans |
|
2,125.00
+13.03%
|
1,880.00
-4.28%
|
1,964.00
+10.09%
|
1,784.00
|
| Tradeand Other Payables Non Current |
|
1,397.00
+63.01%
|
857.00
-20.65%
|
1,080.00
|
—
|
| Non Current Deferred Liabilities |
|
559.00
+9.18%
|
512.00
-9.86%
|
568.00
-42.68%
|
991.00
|
| Non Current Deferred Taxes Liabilities |
|
559.00
+9.18%
|
512.00
-9.86%
|
568.00
-42.68%
|
991.00
|
| Other Non Current Liabilities |
|
2,538.00
-1.86%
|
2,586.00
+8.38%
|
2,386.00
-37.28%
|
3,804.00
|
| Stockholders Equity |
|
52,130.00
+9.37%
|
47,664.00
+23.47%
|
38,603.00
+5.23%
|
36,686.00
|
| Common Stock Equity |
|
52,130.00
+9.37%
|
47,664.00
+23.47%
|
38,603.00
+5.23%
|
36,686.00
|
| Capital Stock |
|
25,527.00
+1.49%
|
25,153.00
+1.14%
|
24,869.00
+0.65%
|
24,709.00
|
| Common Stock |
|
25,527.00
+1.49%
|
25,153.00
+1.14%
|
24,869.00
+0.65%
|
24,709.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
1,996.80
+0.27%
|
1,991.47
+0.18%
|
1,987.88
+0.07%
|
1,986.52
|
| Ordinary Shares Number |
|
1,736.60
+0.28%
|
1,731.70
-0.14%
|
1,734.08
-0.21%
|
1,737.80
|
| Treasury Shares Number |
|
260.20
+0.16%
|
259.77
+2.35%
|
253.81
+2.04%
|
248.72
|
| Retained Earnings |
|
49,781.00
+5.33%
|
47,261.00
+25.85%
|
37,554.00
+6.52%
|
35,257.00
|
| Gains Losses Not Affecting Retained Earnings |
|
-6,001.00
+24.10%
|
-7,906.00
-0.85%
|
-7,839.00
+2.63%
|
-8,051.00
|
| Treasury Stock |
|
17,177.00
+1.98%
|
16,844.00
+5.40%
|
15,981.00
+4.94%
|
15,229.00
|
| Minority Interest |
|
641.00
+170.46%
|
237.00
+5.80%
|
224.00
+2.28%
|
219.00
|
| Other Equity Adjustments |
|
-6,001.00
+24.10%
|
-7,906.00
-0.85%
|
-7,839.00
+2.63%
|
-8,051.00
|
| Total Equity Gross Minority Interest |
|
52,771.00
+10.17%
|
47,901.00
+23.37%
|
38,827.00
+5.21%
|
36,905.00
|
| Total Capitalization |
|
62,026.00
+2.88%
|
60,289.00
+15.49%
|
52,202.00
+1.94%
|
51,208.00
|
| Working Capital |
|
9,500.00
+0.01%
|
9,499.00
+7.59%
|
8,829.00
-9.31%
|
9,735.00
|
| Invested Capital |
|
65,059.00
+5.29%
|
61,789.00
+15.97%
|
53,282.00
-0.33%
|
53,459.00
|
| Total Debt |
|
13,860.00
-7.73%
|
15,021.00
-3.88%
|
15,628.00
-11.79%
|
17,716.00
|
| Net Debt |
|
4,407.00
-32.29%
|
6,509.00
-16.37%
|
7,783.00
+12.94%
|
6,891.00
|
| Capital Lease Obligations |
|
931.00
+3.91%
|
896.00
-5.58%
|
949.00
+0.64%
|
943.00
|
| Net Tangible Assets |
|
22,569.00
+26.02%
|
17,909.00
+193.16%
|
6,109.00
+77.95%
|
3,433.00
|
| Tangible Book Value |
|
22,569.00
+26.02%
|
17,909.00
+193.16%
|
6,109.00
+77.95%
|
3,433.00
|
| Available For Sale Securities |
|
597.00
+7.96%
|
553.00
-0.36%
|
555.00
-0.54%
|
558.00
|
| Investmentin Financial Assets |
|
597.00
+7.96%
|
553.00
-0.36%
|
555.00
-0.54%
|
558.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
9,566.00
+11.78%
|
8,558.00
+17.86%
|
7,261.00
-24.21%
|
9,581.00
|
| Cash Flow From Continuing Operating Activities |
|
9,566.00
+11.78%
|
8,558.00
+17.86%
|
7,261.00
-24.21%
|
9,581.00
|
| Net Income From Continuing Operations |
|
6,524.00
-51.32%
|
13,402.00
+134.18%
|
5,723.00
-17.45%
|
6,933.00
|
| Depreciation Amortization Depletion |
|
3,116.00
-3.17%
|
3,218.00
-0.77%
|
3,243.00
-0.73%
|
3,267.00
|
| Depreciation |
|
1,434.00
+7.01%
|
1,340.00
+4.93%
|
1,277.00
+1.83%
|
1,254.00
|
| Amortization Cash Flow |
|
1,682.00
-10.44%
|
1,878.00
-4.48%
|
1,966.00
-2.33%
|
2,013.00
|
| Depreciation And Amortization |
|
3,116.00
-3.17%
|
3,218.00
-0.77%
|
3,243.00
-0.73%
|
3,267.00
|
| Amortization Of Intangibles |
|
1,682.00
-10.44%
|
1,878.00
-4.48%
|
1,966.00
-2.33%
|
2,013.00
|
| Stock Based Compensation |
|
664.00
-1.34%
|
673.00
+4.50%
|
644.00
-5.99%
|
685.00
|
| Operating Gains Losses |
|
65.00
-86.51%
|
482.00
+282.54%
|
126.00
-41.40%
|
215.00
|
| Gain Loss On Investment Securities |
|
65.00
-86.51%
|
482.00
+282.54%
|
126.00
-41.40%
|
215.00
|
| Change In Working Capital |
|
-803.00
+91.29%
|
-9,217.00
-272.40%
|
-2,475.00
-62.94%
|
-1,519.00
|
| Change In Receivables |
|
-652.00
+5.64%
|
-691.00
-94.10%
|
-356.00
-423.53%
|
-68.00
|
| Changes In Account Receivables |
|
-652.00
+5.64%
|
-691.00
-94.10%
|
-356.00
-423.53%
|
-68.00
|
| Change In Inventory |
|
195.00
+436.21%
|
-58.00
+75.00%
|
-232.00
+83.58%
|
-1,413.00
|
| Change In Prepaid Assets |
|
-1,295.00
-62.69%
|
-796.00
-46.86%
|
-542.00
-622.67%
|
-75.00
|
| Change In Payables And Accrued Expense |
|
949.00
+112.37%
|
-7,672.00
-470.41%
|
-1,345.00
-3735.14%
|
37.00
|
| Change In Payable |
|
949.00
+112.37%
|
-7,672.00
-470.41%
|
-1,345.00
-3735.14%
|
37.00
|
| Change In Account Payable |
|
954.00
+167.98%
|
356.00
+146.84%
|
-760.00
-280.95%
|
420.00
|
| Change In Other Working Capital |
|
—
|
—
|
-585.00
-52.74%
|
-383.00
|
| Investing Cash Flow |
|
-2,422.00
-3.59%
|
-2,338.00
+25.38%
|
-3,133.00
-80.06%
|
-1,740.00
|
| Cash Flow From Continuing Investing Activities |
|
-2,422.00
-3.59%
|
-2,338.00
+25.38%
|
-3,133.00
-80.06%
|
-1,740.00
|
| Net PPE Purchase And Sale |
|
-2,171.00
+1.63%
|
-2,207.00
-0.23%
|
-2,202.00
-23.92%
|
-1,777.00
|
| Purchase Of PPE |
|
-2,171.00
+1.63%
|
-2,207.00
-0.23%
|
-2,202.00
-23.92%
|
-1,777.00
|
| Capital Expenditure |
|
-2,171.00
+1.63%
|
-2,207.00
-0.23%
|
-2,202.00
-23.92%
|
-1,777.00
|
| Net Investment Purchase And Sale |
|
-164.00
-16.31%
|
-141.00
-21.55%
|
-116.00
-251.52%
|
-33.00
|
| Purchase Of Investment |
|
-167.00
+1.18%
|
-169.00
-6.29%
|
-159.00
+14.05%
|
-185.00
|
| Sale Of Investment |
|
3.00
-89.29%
|
28.00
-34.88%
|
43.00
-71.71%
|
152.00
|
| Net Business Purchase And Sale |
|
-105.00
-10600.00%
|
1.00
+100.12%
|
-837.00
-1843.75%
|
48.00
|
| Purchase Of Business |
|
-105.00
|
0.00
+100.00%
|
-877.00
|
0.00
|
| Net Other Investing Changes |
|
18.00
+100.00%
|
9.00
-59.09%
|
22.00
+0.00%
|
22.00
|
| Financing Cash Flow |
|
-6,309.00
-16.75%
|
-5,404.00
+23.79%
|
-7,091.00
+7.14%
|
-7,636.00
|
| Cash Flow From Continuing Financing Activities |
|
-6,309.00
-16.75%
|
-5,404.00
+23.79%
|
-7,091.00
+7.14%
|
-7,636.00
|
| Net Issuance Payments Of Debt |
|
-1,614.00
-200.56%
|
-537.00
+78.30%
|
-2,475.00
-254.08%
|
-699.00
|
| Issuance Of Debt |
|
5.00
-97.76%
|
223.00
+11050.00%
|
2.00
-71.43%
|
7.00
|
| Repayment Of Debt |
|
-1,504.00
-127.88%
|
-660.00
+73.58%
|
-2,498.00
-231.74%
|
-753.00
|
| Long Term Debt Issuance |
|
5.00
-97.76%
|
223.00
+11050.00%
|
2.00
-71.43%
|
7.00
|
| Long Term Debt Payments |
|
-1,504.00
-127.88%
|
-660.00
+73.58%
|
-2,498.00
-231.74%
|
-753.00
|
| Net Long Term Debt Issuance |
|
-1,499.00
-243.02%
|
-437.00
+82.49%
|
-2,496.00
-234.58%
|
-746.00
|
| Net Short Term Debt Issuance |
|
-115.00
-15.00%
|
-100.00
-576.19%
|
21.00
-55.32%
|
47.00
|
| Net Common Stock Issuance |
|
-893.00
+31.04%
|
-1,295.00
-5.54%
|
-1,227.00
+67.67%
|
-3,795.00
|
| Common Stock Payments |
|
-893.00
+31.04%
|
-1,295.00
-5.54%
|
-1,227.00
+67.67%
|
-3,795.00
|
| Common Stock Dividend Paid |
|
-4,116.00
-7.30%
|
-3,836.00
-7.87%
|
-3,556.00
-7.46%
|
-3,309.00
|
| Cash Dividends Paid |
|
-4,116.00
-7.30%
|
-3,836.00
-7.87%
|
-3,556.00
-7.46%
|
-3,309.00
|
| Repurchase Of Capital Stock |
|
-893.00
+31.04%
|
-1,295.00
-5.54%
|
-1,227.00
+67.67%
|
-3,795.00
|
| Proceeds From Stock Option Exercised |
|
396.00
+50.00%
|
264.00
+58.08%
|
167.00
+0.00%
|
167.00
|
| Net Other Financing Charges |
|
-82.00
|
—
|
—
|
—
|
| Changes In Cash |
|
835.00
+2.33%
|
816.00
+127.54%
|
-2,963.00
-1545.37%
|
205.00
|
| Effect Of Exchange Rate Changes |
|
71.00
+173.96%
|
-96.00
-317.39%
|
-23.00
+81.15%
|
-122.00
|
| Beginning Cash Position |
|
7,616.00
+10.44%
|
6,896.00
-30.22%
|
9,882.00
+0.85%
|
9,799.00
|
| End Cash Position |
|
8,522.00
+11.90%
|
7,616.00
+10.44%
|
6,896.00
-30.22%
|
9,882.00
|
| Free Cash Flow |
|
7,395.00
+16.44%
|
6,351.00
+25.54%
|
5,059.00
-35.17%
|
7,804.00
|
| Interest Paid Supplemental Data |
|
545.00
-9.77%
|
604.00
-8.76%
|
662.00
+17.58%
|
563.00
|
| Income Tax Paid Supplemental Data |
|
1,933.00
+12.19%
|
1,723.00
+16.81%
|
1,475.00
-20.87%
|
1,864.00
|
| Change In Income Tax Payable |
|
-5.00
+99.94%
|
-8,028.00
-1272.31%
|
-585.00
-52.74%
|
-383.00
|
| Change In Tax Payable |
|
-5.00
+99.94%
|
-8,028.00
-1272.31%
|
-585.00
-52.74%
|
-383.00
|
| Sale Of Business |
|
0.00
-100.00%
|
1.00
-97.50%
|
40.00
-16.67%
|
48.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-04-02 View
- 42026-03-25 View
- 8-K2026-03-23 View
- 8-K2026-03-09 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-03-03 View
- 42026-02-26 View
- 42026-02-26 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|